HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

A human mAb specific to oncofetal fibronectin selectively targets chronic skin inflammation in vivo.

Abstract
The antibody-based targeted delivery of bioactive agents to sites of angiogenesis is an attractive therapeutic strategy for cancer treatment, but is largely unexplored for chronic inflammatory diseases. In this article, we show that the extra domain B (EDB) domain of fibronectin, a marker of angiogenesis, is expressed in psoriatic lesions, and that the anti-EDB human antibody L19 can selectively localize to chronically inflamed skin in vivo. The L19-based delivery of the cytokines IL10 and IL12 did not improve or worsen inflammation in a mouse model of chronic skin inflammation, which overexpressed vascular endothelial growth factor under the control of the keratin-14 promoter. By contrast, the L19-based targeted delivery of the proinflammatory cytokine IL2 or of the photosensitizer Sn(IV) chlorin e6 resulted in an increased swelling and reddening of inflamed skin. These results indicate that antibodies specific to components of the modified extracellular matrix can selectively accumulate at chronically inflamed sites in vivo. This observation now stimulates the search for bioactive molecules which can be fused to antibodies and which may confer a therapeutic benefit as a result of their preferential accumulation in psoriatic lesions and other sites of inflammation.
AuthorsEveline Trachsel, Manuela Kaspar, Frank Bootz, Michael Detmar, Dario Neri
JournalThe Journal of investigative dermatology (J Invest Dermatol) Vol. 127 Issue 4 Pg. 881-6 (Apr 2007) ISSN: 1523-1747 [Electronic] United States
PMID17185984 (Publication Type: Journal Article, Research Support, N.I.H., Extramural, Research Support, Non-U.S. Gov't)
Chemical References
  • Antibodies, Monoclonal
  • Fibronectins
  • Interleukin-2
  • Metalloporphyrins
  • Photosensitizing Agents
  • Vascular Endothelial Growth Factor A
  • oncofetal fibronectin
  • tin(IV) chlorin e6
  • Interleukin-10
  • Interleukin-12
Topics
  • Animals
  • Antibodies, Monoclonal (immunology)
  • Antibody Affinity
  • Chronic Disease
  • Dermatitis, Atopic (immunology, metabolism, pathology)
  • Drug Delivery Systems
  • Female
  • Fibronectins (immunology)
  • Humans
  • Hypersensitivity, Delayed (immunology, metabolism, pathology)
  • Interleukin-10 (administration & dosage, pharmacology)
  • Interleukin-12 (administration & dosage, pharmacology)
  • Interleukin-2 (administration & dosage, pharmacology)
  • Light
  • Metalloporphyrins (administration & dosage, pharmacology)
  • Mice
  • Mice, Inbred Strains
  • Mice, Transgenic
  • Photosensitizing Agents (administration & dosage, pharmacology)
  • Skin (drug effects, pathology, radiation effects)
  • Vascular Endothelial Growth Factor A (genetics, metabolism)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: